News
House tax bill includes PBM reforms, spread pricing restrictions & orphan drug negotiation changes, with Rep. Guthrie leading ...
Roche said its $50 billion promise to expand its manufacturing footprint in the US has the potential to be 'reassessed.' ...
Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology
Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes ...
Vir Biotech's hepatitis B therapy shows 4% cure rate with doublet (tobevibart/elebsiran) and 10% with triplet therapy, below ...
FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.
The White House outlined plans to force down prices of drugs sold in the US using the threat of tying costs to rates paid by ...
New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...
Welcome back to Endpoints Weekly — thanks for starting your Saturday with us. It was a busy week in the biopharma world. FDA Commissioner Marty Makary … ...
Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...
Lonza said on Friday it does not expect any 'material financial impact' from current and potential pharma-specific tariffs.
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...
Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results